NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
Express News | Neuropace Inc : Leerink Partners Cuts Target Price to $18 From $20
NeuroPace Is Maintained at Equal-Weight by Morgan Stanley
NeuroPace Price Target Cut to $8.00/Share From $9.50 by Morgan Stanley
Express News | Neuropace Inc : Morgan Stanley Cuts Target Price to $8.00 From $9.50
Morgan Stanley Maintains NeuroPace(NPCE.US) With Hold Rating, Cuts Target Price to $8
Morgan Stanley Lowers Price Target on NeuroPace to $8 From $9.50, Keeps Equalweight Rating
Strong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPace
NeuroPace, Inc.'s (NASDAQ:NPCE) Top Owners Are Private Equity Firms With 47% Stake, While 24% Is Held by Institutions
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20
NeuroPace to Participate in Two Healthcare Conferences in May
NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript
Express News | Neuropace Inc : Morgan Stanley Cuts Target Price to $9.50 From $13.00
Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating
Earnings Call Summary | NeuroPace(NPCE.US) Q1 2024 Earnings Conference
NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript
NeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing Challenges
Neuropace's Financial Health: Navigating Risks Tied to RNS System Dominance and Supplier Dependencies
NeuroPace's Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating
12 Health Care Stocks Moving In Thursday's Intraday Session